RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Entry into a Material Definitive Agreement

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

On October 30, 2018, Ritter Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers named therein (the “Purchasers”), to which the Company agreed to sell 6,000 shares of its newly designated Series B convertible preferred stock, with a stated value of $1,000 per share (the “Series B Shares”), together with common stock purchase warrants (the “Warrants”) to purchase 2,307,692 shares of its common stock (representing 50% of the aggregate number of shares of common stock into which the Series B Shares are convertible) to the Purchasers for aggregate gross proceeds of $6 million to the Company (the “Offering”). The initial conversion price of the Series B Shares is $1.30 per share, which is above the $1.23 per share closing price of the Company’s common stock as reported on the Nasdaq Capital Market on October 30, 2018. The initial conversion price of the Series B Shares is subject to customary adjustment in the event of future stock dividends and stock splits. The Warrants are immediately exercisable for a period of five years and have an initial exercise price of $1.30 per share, subject to customary adjustment in the event of future stock dividends and stock splits.

to the terms of the Securities Purchase Agreement, certain Purchasers who owned shares of the Company’s Series A convertible preferred stock were also permitted to exchange (the “Exchange”) at the closing of the Offering, on a 1-for-1 share basis, their shares of Series A convertible preferred stock for shares of the Company’s newly designated Series C convertible preferred stock, with a stated value of $1,000 per share and convertible into shares of the Company’s common stock at an initial conversion price per share of $1.64 (the “Series C Shares” and, together with the Series B Shares, the Warrants and the shares of common stock issuable upon conversion of the Series B Shares and the Series C Shares and upon exercise of the Warrants, the “Securities”). The initial conversion price of the Series C Shares is subject to customary adjustment in the event of future stock dividends and stock splits. The maximum aggregate number of shares of common stock that may be issued by the Company upon conversion of the Series C convertible preferred stock is limited to 1,146,354 shares (the “Exchange Cap”), representing 19.99% of the shares of the Company’s common stock outstanding immediately prior to execution of the Securities Purchase Agreement, unless the Company obtains stockholder approval to issue shares in excess of the Exchange Cap in accordance with the applicable rules of the Nasdaq Capital Market.

The Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers on October 30, 2018, to which it agreed to file a registration statement covering the resale of the common stock issuable upon conversion of the Series B Shares and the Series C Shares and upon exercise of the Warrants acquired by the Purchasers in the Offering and the Exchange, as applicable.

The Offering closed on November 5, 2018. A.G.P./Alliance Global Partners (the “Placement Agent”) served as the exclusive placement agent and Roth Capital Partners acted as a financial advisor for the Offering. to the terms and conditions of the Placement Agency Agreement, entered into by the Company and the Placement Agent on October 30, 2018, the Company agreed to pay the Placement Agent an aggregate cash fee equal to 7% of the aggregate gross proceeds raised in the Offering (less $750,000 paid by one of the Purchasers) and to reimburse the Placement Agent for up to $35,000 of certain of its expenses with respect to the Offering.

The Offering and the Exchange are intended to be exempt from registration to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder. The Securities were not registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

The foregoing description of the Offering and the Exchange is qualified in its entirety by reference to the Securities Purchase Agreement, the Warrants, the Registration Rights Agreement and the Placement Agency Agreement (the “Transaction Documents”), copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. The representations, warranties and covenants contained in Transaction Documents were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to the Transaction Documents, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Transaction Documents are incorporated herein by reference only to provide investors with information regarding the terms of the Transaction Documents, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Commission.

Item 3.02 Unregistered Sales of Equity Securities.

The information called for by this Item 3.02 is contained in Item 1.01, which is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On October 31, 2018, the Company filed Certificates of Designation of Preferences, Rights and Limitations (the “Certificates of Designation”) with the Secretary of State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions, and limitations relating to the Series B Shares and the Series C Shares, respectively. The Certificates of Designation became effective with the Secretary of the State of Delaware upon filing. Copies of the Certificates of Designation will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018.

Item 8.01 Other Events.

On October 31, 2018, the Company issued a press release announcing that it had entered into the Securities Purchase Agreement with the Purchasers. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


RITTER PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1   Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants   LOS ANGELES (October 31,…
To view the full exhibit click here

About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

An ad to help with our costs